Table 5.3.

Clinical status of capsid assembly effectors or modulators

Drug/class	Route	HBV DNA Log reductiona	Company	Clinical trial phase	ClinicalTrials.gov identifier
Morphothiadin (GLS4)/I	Oral	2.3	HEC Pharma, PR China	2	NCT03638076/NCT04147208/NCT04147208
JNJ 56136379/II	Oral	2.9	Janssen, Ireland	2	NCT02662712
ABI-H0731/II	Oral	3.9	Assembly Biosciences, USA	2	NCT03109730/NTC03780543/NTC03577171/NTC03576066/NTC04454567/NTC02908191
ABI-H2158/II	Oral	2.3	Assembly Biosciences, USA	2	NCT04398134
QL-007/	Oral	-	Qilu, PR China	2	NCT04157257/NCT04157699
RG7907 (RO7049389)/I	Oral	3–5	Roche, Switzerland	1	NCT02952924
EDP-514/II	Oral	> 4.0b	Enanta Pharma, USA	1	NCT04470388
ABI-H3733/II	Oral	5.0c	Assembly Biosciences, USA	1	NCT04271592
ZM-H1505R/pyrazole	Oral		ZhiMeng Biopharma, PR China	1	NCT04220801
ALG-000184/II	Oral	5.0b	Aligos Therapeutics, USA/Emory University	1	NCT04536337
GLP-26/II	Oral	1–3b	Emory University, Aligos Therapeutics	Preclinical	n/a
CB-HBV-001/pyrazole	Oral	12c	ZhiMeng Biopharma, PR China	Preclinical	n/a

N/A not applicable

^aHBV DNA Log₁₀ IU/ml in vivo (data obtained from clinical trials)

^bLog₁₀ decrease in HBV DNA (data obtained from mice models)

^cHBV DNA, EC₅₀ (nM) in vitro